Greider, a professor of molecular biology and genetics at Johns Hopkins University, visited UCSB for three days to talk to MCDB faculty, deliver two lectures in the Frontiers of Cancer Research Series, and was honored as the first UCSB alumna to win a Nobel Prize. Greider graduated from UCSB in 1983 and conducted research as an undergraduate the laboratory of Leslie Wilson, an MCDB faculty member.
An interdisciplinary team of researchers mainly at UC Santa Barbara, including Ph.D. student Rebecca Werlin in the laboratory of Professor Eduardo Orias in MCDB, has produced a groundbreaking study of how nanoparticles are able to biomagnify in a simple microbial food chain. This study was published in the journal Nature Nanotechnology.
Remarkable progress in understanding how stem cell biology works has been reported by a team of scientists led by MCDB professor Ken Kosik. Their research using microRNA profiling revealed two distinct p53-related human pluripotent stem cell states and has been published in the journal Cell Stem Cell.
A study published in the November 18th issue of the journal Nature shows that bacteria express stick-like contact-dependent inhibitor (CDI) proteins on their cell surface that contain an embedded toxin at the tip. The toxin is delivered to neighboring cells upon direct cell contact. The work is the result of collaboration between the laboratories of Christopher Hayes, David Low, Peggy Cotter and Stephen Poole in MCDB.
An international collaboration between UC Santa Barbara, the Keck School of Medicine of the University of Southern California (USC), and several other research institutions, is bringing together leaders in the fields of stem cell biology, basic science, and ophthalmology to develop a treatment for blindness caused by age-related macular degeneration.
The laboratories of Dr. Mary Ann Jordan and Dr. Leslie Wilson have elucidated the mechanism of action of DM1, a synthetic derivative of the natural product maytansine, from plants of the genus Maytenus. To reduce the highly toxic side effects of the natural maytansine drug, scientists from ImmunoGen, Inc., synthesized DM1 and attached it to antibodies that specifically target cancer cells of various types. Eight drugs comprised of antibodies linked to DM1 are now in clinical trials and show as much as 100% shrinkage of the targeted tumor.
Rep. Lois Capps, D-Santa Barbara, spent two hours Tuesday afternoon touring the UCSB-Sanford Burnham Center for Nanomedicine.
MCDB scientists led by Joel Rothman have discovered that a protein that helps cells sticks together also keeps them from dividing excessively, a hallmark of cancer progression. The discovery could lead to new ways to control cancer and was described in a paper published in the September 14 issue of Proceedings of the National Academy of Sciences.
Four scientists from UC Santa Barbara contributed to the sequencing of the genome of a Great Barrier Reef marine sponge, from a 650 million-year-old group of organisms -- a project that indicates there were astonishingly rich genetic resources available at the dawn of the animal kingdom. The sequencing also reveals some basic information about cancer. The findings were published in the August 5th issue of the scientific journal Nature.
In a transformative paper published in the May 21 issue of the journal Science, Erkki Ruoslahti, distinguished professor, Kazuki Sugahara, and fellow researchers at UCSB's MCDB department and the Sanford-Burnham Medical Research Institute, have shown that a chain of amino acids (called the iRGD peptide), when co-administered with anti-cancer drugs in mice, make those drugs more effective by guiding them to solid tumors and helping them penetrate deeply into tumor tissue.